Archives
-
Latrunculin B in Actin and Viral Entry Research
2026-10-09
Latrunculin B is a pharmacological tool for studying actin filament assembly and cytoskeletal organization. In a grass carp reovirus study, it did not inhibit viral entry, whereas several inhibitors associated with clathrin-mediated endocytosis did. The finding supports a limited, context-specific interpretation rather than a general conclusion that actin is irrelevant to virus entry.
-
ConA Targets Conserved Coronavirus Spike Glycans
2026-10-09
Guo et al. report that concanavalin A inhibits coronavirus entry by recognizing conserved high-mannose N-glycans near the spike S2′ cleavage site, rather than rapidly changing receptor-binding epitopes. Convergent cell, biochemical, pseudovirus, authentic-virus, and animal evidence supports glycan-dependent interference with spike activation, while clinical translation remains unestablished.
-
HSP90 Modulates RNA Foci in Myotonic Dystrophy
2026-10-08
Johnson and colleagues used an unbiased small-molecule RNA-FISH screen to identify HSP90 as a regulator of pathogenic DMPK mRNA and CUG-repeat RNA foci in myotonic dystrophy type 1. The study further connects HSP90 activity to p-STAT3 in undifferentiated myoblasts while showing that differentiation reverses the DMPK response, emphasizing cell-state dependence in RNA-foci biology.
-
Anti-RPS6 Antibody: Reading Biosynthetic Growth
2026-10-08
The Anti-RPS6 antibody MA4974 offers a total-RPS6 perspective on ribosome-associated growth biology. This article explains how to interpret Western blot, ICC/IF, and immunoprecipitation evidence within the LRRC8A–CAV1–KRAS/EGFR framework while separating abundance from phosphorylation and causality.
-
740 Y-P and the Next Frontier of PI3K Translation
2026-10-07
A thought-leadership analysis of 740 Y-P as a PI 3-kinase activator, using recent ajugol research to examine PI3K/AKT/mTOR biology, causal validation, translational boundaries, and strategic applications across cell-based research.
-
Generating Right Ventricular-Like Cardiomyocytes
2026-10-07
Saito et al. report a developmental-biology-informed strategy for producing right ventricular-like cardiomyocytes from human pluripotent stem cells by shifting cardiac progenitor identity toward the anterior second heart field. The resulting cells showed chamber-associated gene-expression and functional differences, supporting more precise in vitro models of right-sided cardiac disease while leaving important questions about maturation and clinical transferability.
-
PEP, cGAS–STING, and Healthy Aging
2026-10-06
A 2026 Nature Aging study identifies phosphoenolpyruvate (PEP) as an endogenous metabolic brake on cGAS–STING-driven inflammation. Its mouse and human findings connect age-related PEP dynamics with inflammaging, neuroinflammation, and healthy-aging traits, while leaving important questions about human translation and metabolite specificity.
-
Miltefosine: Signaling, Leukopenia, and Evidence
2026-10-06
Miltefosine is a phospholipid analogue with context-dependent effects on cell signaling. A 2025 preclinical study reported that it promoted neutrophil differentiation and improved blood-cell recovery in an irradiation-induced mouse model through Ras/MEK/ERK-associated signaling, while supplier-described oncology research emphasizes PI3K/Akt pathway modulation. The evidence is promising but remains limited to cell and animal models, with no established clinical efficacy for leukopenia.
-
Indomethacin and Beige Fat: A Translational Lens
2026-10-05
A mechanistic, evidence-aware analysis of how Indomethacin can help frame inflammation, lipid metabolism, and membrane signaling questions alongside new evidence linking SEMA3E to beige adipocyte thermogenesis.
-
BHQ and SERCA: Evidence, Mechanism and Limits
2026-10-05
Five evidence-focused questions explain what 2,5-di-tert-butylbenzene-1,4-diol (BHQ) reveals about SERCA, calcium homeostasis disruption and hematopoietic stem-cell mobilization, while separating reported findings from interpretation and highlighting limits on clinical and cross-domain conclusions.
-
Intravesical p21 mRNA–LNP Therapy in Bladder Cancer
2026-10-04
A 2026 FASEB Journal study evaluates lipid nanoparticles carrying chemically modified p21 mRNA for localized bladder cancer treatment. Its findings support intravesical tumor-suppressor replacement in cell and mouse models, while leaving important questions about durability, patient selection, and clinical translation unresolved.
-
Lactate–GPR81 Signaling Drives Insulin-Independent Uptake
2026-10-03
A 2026 Cell Research study identifies lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and proposes a GPR81–FARP1–RAC1–GLUT4 signaling axis. The findings connect exercise-associated lactate production with metabolic control while also defining important boundaries around animal-model evidence, pharmacological interpretation, and human genetic associations.
-
Proteoform-Specific Drug Interactions in Native Membranes
2026-10-02
Lutomski and colleagues introduce a native mass-spectrometry workflow that releases membrane proteins and signaling complexes directly from retina rod disc membranes, preserving proteoform and lipid-context information. The study shows how rhodopsin, G-protein lipidation, and PDE6 interactions with vardenafil and sildenafil can be resolved at the proteoform level, providing a more realistic framework for evaluating drug selectivity and off-target binding.
-
CKI 7 dihydrochloride: CK1 Research Workflows
2026-10-01
CKI 7 dihydrochloride gives researchers a practical small-molecule route to perturb Casein kinase 1 in biochemical and cell-based assays. This guide connects Wnt, apoptosis, circadian, and cancer workflows with a reference-study-inspired strategy for separating pathway effects from unrelated toxicity.
-
Sodium Phosphate Dibasic: Buffering Guide
2026-10-01
Sodium phosphate dibasic, or Na2HPO4, is a water-soluble phosphate salt used to stabilize pH in biological assay buffers. Product B7293 is listed as a 98.00% research reagent with a molecular weight of 141.96 g/mol, while formulation-specific compatibility and solution-storage limits require separate validation.